Peregrine Pharmaceuticals (NASDAQ:PPHM), a top biotech stocks, working for improving patient lives by developing high quality products for biotech and pharmaceutical firms and advancing its R&D pipeline, reported the publication of promising proof-of-concept report for a unique exosome-dependent cancer detection platform.
The report of the trial, performed at University of Texas Southwestern Medical Center, highlighted researchers were able to differentiate between patients with ovarian tumors and healthy subjects depending on the levels of exosomes containing PS found in their plasma. Moreover, assessment of the PS-positive exosome marks permitted researchers to distinguish between benign and malignant tumors. This report was recently issued online by Oncotarget.
The biotech stock of Peregrine is currently developing the exosome-based cancer diagnostic know-how, approved from UT Southwestern in July 2016, with an objective of advancing an optimized test for clinical assessment. As part of these measures, the firm is in the process of finding a strategic associate for collaboration on advancing and commercializing the know-how. The platform is dependent on the diagnostic prospect of tumor exosomes, which are minuscule vesicles from tumor cells administered into the blood as tumors develop.
Tumor derived exosomes shows PS on their surface as a noticeable marker. It is assumed that even small tumors commence to issue PS-positive exosomes and therefore the ability to identify these exosomes in the blood seem to be a sign of the tumor presence.
In the study issued by Oncotarget, plasma tasters from 34 subjects with ovarian tumors and ten healthy subjects were assessed for the PS-expressing exosomes presence in a blinded test. Report showed that those subjects with malignant ovarian cancer showed considerably increased blood PS exosome levels compared to those with benign tumors and the benign and malignant groups displayed considerably higher blood PS exosome marks than the healthy subjects.
This preliminary proof-of-concept data is promising as they seem to back the underlying notion that the extent of PS-positive exosome points in blood could be a modest way to notice and monitor cancer.